Alzheimer's disease
In a recent study, the 48-protein panel improved the diagnostic performance of existing Alzheimer's markers and helped predict progression of the disease.
FDA's recommendation that Alzheimer's patients be tested for APOE status prior to starting the drug could lead to new regulatory approvals and payor coverage.
Top Five Articles on 360Dx Last Week: NYS LDT Database; August's FDA 510(k) Clearances; More
Last week, readers were most interested in a story about New York state's LDT database and the insight it may provide into the broader landscape.
Researchers and clinicians have highlighted the lack of data supporting the test and warned that false positive results could further tax overburdened memory clinics.
Circular Genomics, Washington University Researcher to Explore circRNA as Alzheimer's Biomarker
The collaborators will assess the associations between blood circRNA, memory, and aging, with the aim of developing a circRNA-based Alzheimer’s assay.